Close

Dr Amanda Fortes Francisco

Assistant Professor

London School of Hygiene and Tropical Medicine
Keppel Street - room 497
London
WC1E 7HT
United Kingdom

I obtained a BSc in Nutrition and an MSc and PhD in Biological Sciences, both from the Federal University of Ouro Preto in Brazil. In 2012 I was awarded a scholarship from The Brazilian National Council for Scientific and Technological Development to work on Trypanosoma cruzi heart pathology in John's lab where I undertook this post-doctoral for 2 years.

 

In 2014 I started at the school funded by Drugs for Neglected Diseases initiative (DNDi). DNDi is a non-profit research and development organization that is developing new treatments for neglected diseases. My main projects currently are related to drug discovery and T. cruzi/T. brucei pathogenesis using in vivo bioluminescent imaging systems.

 

I am a member of the BBSRC LIDo DTP EDI  and LSHTM ITD EDI committees.  

Affiliations

Department of Infection Biology
Faculty of Infectious and Tropical Diseases

Teaching

Tutor on Distance Learning module IDM601: Research Design, Management and Analysis, 2023 – current.

Tutor on Distance Learning module IDM203: Parasitology, 2019 – 2022.

Lecture on Molecular and Cell Biology of Infectious Disease (3260), 2022 – current.

Supervision and training in animal and histological techniques applied to research.

Research

Chagas Heart Disease cardiomyopathy, with a focus on inflammation and fibrosis.
Exploit in vivo imaging technology to study trypanosomes pathogenesis and assess drug effectiveness.
Research Area
Chemotherapy
Disease control
Drug discovery and development
Protozoa
Public health
Trypanosomes
Immunopathology
Parasitology
Pathology
Parasites
Cardiovascular system
Digestive system
Disease and Health Conditions
Chagas Disease
Neglected Tropical Diseases (NTDs)
Infectious diseases
Cardiovascular diseases
African trypanosomiasis
Chronic diseases
Heart disease
Tropical diseases
Region
World

Selected Publications

Short-course combination treatment for experimental chronic Chagas disease.
González, S; WALL, RJ; Thomas, J; Braillard, S; Brunori, G; Camino Díaz, I; Cantizani, J; Carvalho, S; Castañeda Casado, P; Chatelain, E; Cotillo, I; Fiandor, JM; FRANCISCO, AF; Grimsditch, D; Keenan, M; KELLY, JM; Kessler, A; Luise, C; Lyon, JJ; MacLean, L; Marco, M; Martin, JJ; Martinez Martinez, MS; Paterson, C; Read, KD; ... De Rycker, M.
2023
Science translational medicine
Cardiac Abnormalities in a Predictive Mouse Model of Chagas Disease.
FRANCISCO, AF; Sousa, GR; Vaughan, M; Langston, H; KHAN, A; Jayawardhana, S; TAYLOR, MC; Lewis, MD; KELLY, JM;
2023
Pathogens
Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice.
Jayawardhana, S; Ward, AI; FRANCISCO, AF; Lewis, MD; TAYLOR, MC; KELLY, JM; Olmo, F;
2023
PLoS Pathogens
Preclinical data do not support the use of amiodarone or dronedarone as antiparasitic drugs for Chagas disease at the approved human dosing regimen
FRANCISCO, AF; Chen, G; Wang, W; Sykes, ML; Escudié, F; Scandale, I; Olmo, F; Shackleford, DM; Zulfiqar, B; Kratz, JM; Pham, T; Saunders, J; Hu, M; Avery, VM; Charman, SA; KELLY, JM; Chatelain, E;
2023
Frontiers in tropical diseases
Bis-6-amidino-benzothiazole Derivative that Cures Experimental Stage 1 African Trypanosomiasis with a Single Dose.
Racané, L; Ptiček, L; Kostrun, S; Raić-Malić, S; TAYLOR, MC; DELVES, M; ALSFORD, S; Olmo, F; FRANCISCO, AF; KELLY, JM;
2023
Journal of medicinal chemistry
Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infections.
Rao, SP S; Gould, MK; Noeske, J; Saldivia, M; Jumani, RS; Ng, PS; René, O; Chen, Y-L; Kaiser, M; Ritchie, R; FRANCISCO, AF; Johnson, N; Patra, D; Cheung, H; Deniston, C; Schenk, AD; Cortopassi, WA; Schmidt, RS; Wiedemar, N; Thomas, B; Palkar, R; Ghafar, NA; Manoharan, V; Luu, C; Gable, JE; ... Diagana, TT.
2023
Science
Collaborative Virtual Screening Identifies a 2-Aryl-4-aminoquinazoline Series with Efficacy in an In Vivo Model of Trypanosoma cruzi Infection.
Tawaraishi, T; Ochida, A; Akao, Y; Itono, S; Kamaura, M; Akther, T; Shimada, M; Canan, S; Chowdhury, S; Cao, Y; Condroski, K; Engkvist, O; FRANCISCO, A; Ghosh, S; Kaki, R; KELLY, JM; Kimura, C; Kogej, T; Nagaoka, K; Naito, A; Pairaudeau, G; Radu, C; Roberts, I; Shum, D; Watanabe, N-A; ... Perry, B.
2023
Journal of medicinal chemistry
Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers for monitoring parasitological cure.
FRANCISCO, AF; Saade, U; Jayawardhana, S; Pottel, H; Scandale, I; Chatelain, E; Liehl, P; KELLY, JM; Zrein, M;
2022
PLoS neglected tropical diseases
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
Ang, CW; Lee, BM; Jackson, CJ; Wang, Y; Franzblau, SG; FRANCISCO, AF; KELLY, JM; Bernhardt, PV; Tan, L; West, NP; Sykes, ML; Hinton, AO; Bolisetti, R; Avery, VM; Cooper, MA; Blaskovich, MA T;
2022
Journal of Medicinal Chemistry
Invariant surface glycoprotein 65 of Trypanosoma brucei is a complement C3 receptor.
Macleod, OJ S; Cook, AD; Webb, H; Crow, M; Burns, R; Redpath, M; Seisenberger, S; Trevor, CE; Peacock, L; Schwede, A; Kimblin, N; FRANCISCO, AF; Pepperl, J; Rust, S; Voorheis, P; Gibson, W; TAYLOR, MC; Higgins, MK; Carrington, M;
2022
Nature Communications
See more information